September 1, 2012 (Vol. 32, No. 15)

Paul Chapman is now president and CEO of Quanterix. Previously, Chapman was vp of BioPharm Process Solutions at EMD Millipore. Additionally, Chapman’s experience includes being international business development manager at Roche Molecular Diagnostics.

Paul Chapman

NovImmune added Michael Steinmetz, Ph.D., to its board of directors and David Slack as head of corporate and business development…DARA Biosciences appointed Stephen O. Jaeger to its board of directors…DBV Technologies named Stef Koppelman, Ph.D., as general scientific advisor…NanoString Technologies added Greg Norden to its board of directors…Dominic Spinella, Ph.D., is now vp of clinical development and medical affairs at Biodesix…Galenea appointed Timothy A. Ryan, Ph.D., to its scientific advisory board…BioStorage Technologies named Jason Huang as general manager of Asia Pacific.

Shimadzu U.K. appointed Andy Winn as a product specialist for atomic absorption, inductively coupled plasma, and total organic carbon in its spectroscopy group. Winn was formerly with Thermo Fisher Scientific before moving to Varian U.K. and Agilent Technologies.

Andy Winn

HYCOR Biomedical added John Kershaw to its board of directors…Morria Biopharmaceuticals appointed Charles Serhan, Ph.D., to its scientific advisory board…Brian Klein, M.D., joined Stifel Nicolaus as vp and senior analyst of its biotechnology sector…Sancilio and Company added Alan Dunton, M.D., Patrick Gray, Rod Jackson, Dennis Langer, M.D., and Kelly Perkins to its board of directors…Firefly BioWorks elected Victor R. Ambros, Ph.D., to its scientific advisory board…ADMA Biologics appointed Lawrence Guiheen to its board of directors.

ADC Therapeutics added Patrick van Berkel, Ph.D., as svp of R&D. Dr. van Berkel has worked in the biotech industry for more than 20 years. Previously, he served with Genmab as vp of chemistry, manufacturing, and control R&D. Prior to Genmab, Dr. van Berkel worked for Crucell.

Patrick van Berkel, Ph.D.

Lawrence Bloch, M.D., J.D., joined Infinity Pharmaceuticals as evp, CFO, and CBO…Molecular Devices named Sean J. Morrison, Tobias Meyer, Paul Johnston, Tobin J. Dickerson, and Pam Hawley-Nelson, Ph.D., to its scientific advisory board…Collegium Pharmaceutical appointed Gino Santini to its board of directors.

Caisson Biotech named Glenn E. Nedwin, Ph.D., as CEO and president. Dr. Nedwin has more than 30 years of experience in the pharmaceutical and biotechnology industries. He has held positions as president of Novozymes and evp of the Genencor division of Danisco.

Glenn E. Nedwin, Ph.D.

James Mond, M.D., Ph.D., is now chief medical and scientific officer at ADMA Biologics…Oncothyreon hired Guy Cipriani as vp, business development…Empire Genomics added Michael J. Becich, M.D., Ph.D., to its scientific advisory board…A.P. Pharma appointed Robert Rosen to its board of directors.

Shannon Gordon joined Theorem Clinical Research as vp of global project management. Gordon has more than 14 years of operational and leadership experience. Previously she was senior director, project delivery at PRA International.

Shannon Gordon

Endocyte named Marc Kozin to its board of directors…Horizon Discovery appointed Richard Vellacott as CFO…Gary L. Smith, Ph.D., joined med fusion as COO…EMD Serono appointed Thorsten Eickenhorst, M.D., as U.S. CMO.

Array BioPharma named Andrew Robbins as svp, commercial operations. Robbins has a 15-year career in the pharmaceutical industry. Most recently he was at Hospira as general manager and vp of the U.S. Alternate Site business unit. Previously, he was vp of corporate development.

Andrew Robbins

Send your People Announcements to [email protected].

Previous articleLegalizing Medicinal Marijuana
Next articleTop 20 Pharma-Friendly Congress Members